Stock PSNL PERSONALIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Personalis, Inc. Stock

Equities

PSNL

US71535D1063

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
1.265 USD +1.20% Intraday chart for Personalis, Inc. -1.94% -39.76%
03-26 Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring CI
02-29 Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating MT

Financials

Sales 2024 * 74.1M 101M Sales 2025 * 85.88M 117M Capitalization 64.78M 88.55M
Net income 2024 * -77M -105M Net income 2025 * -71M -97.05M EV / Sales 2024 * 0.78 x
Net cash position 2024 * 6.79M 9.28M Net cash position 2025 * 96.61M 132M EV / Sales 2025 * -0.37 x
P/E ratio 2024 *
-0.8 x
P/E ratio 2025 *
-0.94 x
Employees 224
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.18%
More Fundamentals * Assessed data

Chart Personalis, Inc.

Dynamic Chart

Latest news about Personalis, Inc.

Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring CI
Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating MT
Transcript : Personalis, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (PSNL) PERSONALIS Reports Q4 Revenue $19.7M, vs. Street Est of $19.3M MT
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024 CI
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Personalis to Offer ClearNote's Epigenomic Platform in Partnership MT
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology CI
Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay CI
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Personalis, Tempus Labs to Collaborate on NeXT Personal Dx Detection Test MT
Personalis and Tempus Enter into Strategic Collaboration to Advance Cancer Testing CI
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform MT
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers CI
More news

Latest transcript on Personalis, Inc.

Logo Personalis, Inc.
Personalis, Inc., Q4 2023 Earnings Call, Feb 28, 2024
More transcripts

Analyst Recommendations on Personalis, Inc.

Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating MT
Needham Cuts Price Target on Personalis to $2.30 From $7, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Personalis to $7.50 From $10, Maintains Buy Rating MT
Needham Trims Price Target on Personalis to $7 From $8, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Personalis to $5 From $11, Maintains Equal-Weight Rating MT
More recommendations

Press releases Personalis, Inc.

Personalis to Announce First Quarter 2024 Financial Results BU
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference BU
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting BU
Personalis Announces Publication Validating NeXT Personal Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring AQ
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring BU
More press releases

News in other languages on Personalis, Inc.

Moderna : nouveaux essais cliniques de vaccins anticancéreux
Evaxion utilizará la plataforma ImmunoID NeXT® de Personalis para evaluar la eficacia de su terapia combinada para el tratamiento del melanoma avanzado
Evaxion nutzt ImmunoID NeXT Platform® von Personalis zur Untersuchung der Wirksamkeit einer Kombinationstherapie für Melanome in späten Stadien
Evaxion gebruikt het ImmunoID NeXT Platform® van Personalis om de werkzaamheid van combinatietherapie voor melanoom in een laat stadium te evalueren
Evaxion s’apprête à utiliser l’ImmunoID NeXT Platform® de Personalis pour évaluer l’efficacité d’une thérapie combinée contre le mélanome de stade avancé
More news

Quotes and Performance

1 day+1.20%
1 week-1.94%
Current month-15.10%
1 month-11.54%
3 months-7.66%
6 months+25.25%
Current year-39.76%
More quotes

Highs and lows

1 week
1.18
Extreme 1.18
1.42
1 month
1.18
Extreme 1.18
1.54
Current year
1.12
Extreme 1.12
2.35
1 year
0.89
Extreme 0.8906
2.60
3 years
0.89
Extreme 0.8906
28.47
5 years
0.89
Extreme 0.8906
53.46
10 years
0.89
Extreme 0.8906
53.46
More quotes

Managers and Directors - Personalis, Inc.

Managers TitleAgeSince
Christopher Hall CEO
 Chief Executive Officer 55 22-10-30
Aaron Tachibana DFI
 Director of Finance/CFO 63 19-02-28
Richard Chen CTO
 Chief Tech/Sci/R&D Officer 53 11-10-31
Members of the board TitleAgeSince
Arthur Bowman BRD
 Director/Board Member 77 19-04-30
Kenneth Widder BRD
 Director/Board Member 71 23-06-13
Woodrow Myers BRD
 Director/Board Member 70 21-03-05
More insiders

ETFs positioned on Personalis, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD ETF Leverage Shares 1x ARK Genomic Tracker ETP - USD
0.67% 1 M€ 0.00% -
More ETFs positioned on Personalis, Inc.

Quotes

Date Price Change Volume
24-04-26 1.265 +1.20% 49,108
24-04-25 1.25 -3.85% 147,326
24-04-24 1.3 -5.80% 162,172
24-04-23 1.38 +9.52% 176,072
24-04-22 1.26 -2.33% 203,197

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm

More quotes

Company Profile

Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
Sector
Biotechnology & Medical Research
Calendar
2024-05-08 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Personalis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.265 USD
Average target price
4.75 USD
Spread / Average Target
+275.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PERSONALIS, INC. Stock Personalis, Inc.
-39.76% 64.78M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PSNL Stock